Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Heerspink, A. Stack, R. Terkeltaub, Tom Greene, L. Inker, M. Bjursell, S. Perl, T. Rikte, F. Erlandsson, V. Perkovic (2021)
Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemiaNephrology Dialysis Transplantation, 37
Haaland reports Consultancy: AstraZeneca, Guidepoint Global, National Kidney Foundation, Prometic Life Sciences, and Value Analytics Labs; and Ownership Interest
(2023)
and Drug Administration; Center for Drug Evaluation and Research
A. Zuilen, J. Wetzels, M. Bots, Peter Blankestijn (2008)
MASTERPLAN: study of the role of nurse practitioners in a multifactorial intervention to reduce cardiovascular risk in chronic kidney disease patients.Journal of nephrology, 21 3
Pietro Zucchelli (deceased)
Anushka Patel, S. MacMahon, J. Chalmers, B. Neal, L. Billot, M. Woodward, M. Marre, M. Cooper, P. Glasziou, D. Grobbee, P. Hamet, S. Harrap, S. Heller, Li-sheng Liu, G. Mancia, C. Mogensen, C. Pan, N. Poulter, A. Rodgers, B. Williams, Severine Bompoint, B. Galan, R. Joshi, F. Travert (2008)
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.The New England journal of medicine, 358 24
H. Heerspink, G. Law, K. Psachoulia, K. Connolly, C. Whatling, H. Ericsson, Jane Knöchel, E. Lindstedt, Iain MacPhee (2021)
Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKDKidney International Reports, 6
B. Neuen, M. Weldegiorgis, W. Herrington, T. Ohkuma, Margaret Smith, M. Woodward (2021)
Changes in GFR and Albuminuria in Routine Clinical Practice and the Risk of Kidney Disease Progression.American journal of kidney diseases : the official journal of the National Kidney Foundation
ROAD: Fan Fan Hou
(2011)
A nursecoordinated model of care versus usual care for stage 3/4 chronic kidney disease in the community: a randomized controlled trial
Fernando Caravaca-Fontán
(2017)
NEFIGAN Trial Investigators: targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebocontrolled phase 2b trial
C. Baigent, M. Landray, C. Reith, J. Emberson, D. Wheeler, C. Tomson, C. Wanner, V. Krane, A. Cass, J. Craig, B. Neal, Lixin Jiang, L. Hooi, A. Levin, L. Agodoa, M. Gaziano, B. Kasiske, R. Walker, Z. Massy, B. Feldt-Rasmussen, U. Krairittichai, V. Ophascharoensuk, B. Fellström, H. Holdaas, V. Tesar, A. Więcek, D. Grobbee, D. Zeeuw, C. Grönhagen‐Riska, T. Dasgupta, D. Lewis, W. Herrington, M. Mafham, W. Majoni, K. Wallendszus, R. Grimm, T. Pedersen, J. Tobert, J. Armitage, A. Baxter, C. Bray, Yiping Chen, Zhengming Chen, M. Hill, C. Knott, S. Parish, D. Simpson, P. Sleight, A. Young, R. Collins (2011)
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialLancet, 377
(2019)
Mixedeffectsmodels for slope-based endpoints in clinical trials of chronic kidney disease
FDA Approves First Drug to Decrease Urine Protein in IgA Nephropathy, a Rare Kidney Disease
R. Komers, U. Diva, Jula Inrig, A. Loewen, H. Trachtman, W. Rote (2020)
Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental GlomerulosclerosisKidney International Reports, 5
A. Levey, L. Stevens, C. Schmid, Y. Zhang, Alejandro Castro, H. Feldman, J. Kusek, P. Eggers, F. Lente, T. Greene, J. Coresh (2009)
A new equation to estimate glomerular filtration rate.Annals of internal medicine, 150 9
ALTITUDE: Hans-Henrik Parving
A. Levey, R. Gansevoort, J. Coresh, L. Inker, H. Heerspink, M. Grams, T. Greene, H. Tighiouart, K. Matsushita, S. Ballew, Y. Sang, E. Vonesh, Jian Ying, Tom Manley, D. Zeeuw, K. Eckardt, A. Levin, V. Perkovic, Luxia Zhang, K. Willis (2019)
Change in Albuminuria and GFR as End Points for Clinical Trials in Early Stages of CKD: A Scientific Workshop Sponsored by the National Kidney Foundation in Collaboration With the US Food and Drug Administration and European Medicines Agency.American journal of kidney diseases : the official journal of the National Kidney Foundation
L. Inker, Hiddo Lambers-Heerspink, H. Tighiouart, Juhi Chaudhari, Shiyuan Miao, U. Diva, A. Mercer, G. Appel, J. Donadio, J. Floege, P. Li, B. Maes, F. Locatelli, M. Praga, F. Schena, A. Levey, T. Greene (2021)
Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis.American journal of kidney diseases : the official journal of the National Kidney Foundation
T. Greene, C. Teng, L. Inker, A. Redd, Jian Ying, M. Woodward, J. Coresh, A. Levey (2014)
Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study.American journal of kidney diseases : the official journal of the National Kidney Foundation, 64 6
M. Goicoechea, S. Vinuesa, Ú. Verdalles, E. Verde, N. Macías, Alba Santos, A. José, Santiago Cedeño, Tania Linares, J. Luño (2015)
Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial.American journal of kidney diseases : the official journal of the National Kidney Foundation, 65 4
M. Oshima, M. Jun, T. Ohkuma, T. Toyama, T. Wada, M. Cooper, S. Hadjadj, P. Hamet, S. Harrap, G. Mancia, M. Marre, B. Williams, J. Chalmers, M. Woodward, V. Perkovic (2019)
The relationship between eGFR slope and subsequent risk of vascular outcomes and all-cause mortality in type 2 diabetes: the ADVANCE-ON studyDiabetologia, 62
H. Skali, H. Uno, A. Levey, L. Inker, M. Pfeffer, S. Solomon (2011)
Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation.American heart journal, 162 3
J. Barratt, B. Rovin, U. Diva, A. Mercer, R. Komers (2019)
Implementing the Kidney Health Initiative Surrogate Efficacy Endpoint in Patients With IgA Nephropathy (the PROTECT Trial)Kidney International Reports, 4
L. Inker, H. Heerspink, H. Tighiouart, A. Levey, J. Coresh, R. Gansevoort, Andrew Simon, Jian Ying, G. Beck, C. Wanner, J. Floege, P. Li, V. Perkovic, E. Vonesh, T. Greene (2019)
GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.Journal of the American Society of Nephrology : JASN
Janssen Pharmaceutical, Morphosys, and Retrophin; Honoraria: UpToDate; and Advisory or Leadership Role: Kidney International, Nephrology, UpToDate; Nephrology Dialysis and Transplantation
Anushka Patel (2007)
Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trialThe Lancet, 370
H. Heerspink, T. Greene, H. Tighiouart, R. Gansevoort, J. Coresh, Andrew Simon, T. Chan, F. Hou, J. Lewis, F. Locatelli, M. Praga, F. Schena, A. Levey, L. Inker (2019)
Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials.The lancet. Diabetes & endocrinology, 7 2
Appel reports Consultancy: Achillion, Alexion
Significance StatementChanges in albuminuria and GFR slope are individually used as surrogate end points in clinical trials of CKD progression, and studies have demonstrated that each is associated with treatment effects on clinical end points. In this study, the authors sought to develop a conceptual framework that combines both surrogate end points to better predict treatment effects on clinical end points in Phase 2 trials. The results demonstrate that information from the combined treatment effects on albuminuria and GFR slope improves the prediction of treatment effects on the clinical end point for Phase 2 trials with sample sizes between 100 and 200 patients and duration of follow-up ranging from 1 to 2 years. These findings may help inform design of clinical trials for interventions aimed at slowing CKD progression.BackgroundChanges in log urinary albumin-to-creatinine ratio (UACR) and GFR slope are individually used as surrogate end points in clinical trials of CKD progression. Whether combining these surrogate end points might strengthen inferences about clinical benefit is unknown.MethodsUsing Bayesian meta-regressions across 41 randomized trials of CKD progression, we characterized the combined relationship between the treatment effects on the clinical end point (sustained doubling of serum creatinine, GFR <15 ml/min per 1.73 m2, or kidney failure) and treatment effects on UACR change and chronic GFR slope after 3 months. We applied the results to the design of Phase 2 trials on the basis of UACR change and chronic GFR slope in combination.ResultsTreatment effects on the clinical end point were strongly associated with the combination of treatment effects on UACR change and chronic slope. The posterior median meta-regression coefficients for treatment effects were −0.41 (95% Bayesian Credible Interval, −0.64 to −0.17) per 1 ml/min per 1.73 m2 per year for the treatment effect on GFR slope and −0.06 (95% Bayesian Credible Interval, −0.90 to 0.77) for the treatment effect on UACR change. The predicted probability of clinical benefit when considering both surrogates was determined primarily by estimated treatment effects on UACR when sample size was small (approximately 60 patients per treatment arm) and follow-up brief (approximately 1 year), with the importance of GFR slope increasing for larger sample sizes and longer follow-up.ConclusionsIn Phase 2 trials of CKD with sample sizes of 100–200 patients per arm and follow-up between 1 and 2 years, combining information from treatment effects on UACR change and GFR slope improved the prediction of treatment effects on clinical end points.
Journal of the American Society of Nephrology – Wolters Kluwer Health
Published: Jun 15, 2023
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.